SCYNEXIS Inc banner

SCYNEXIS Inc
F:135A

Watchlist Manager
SCYNEXIS Inc Logo
SCYNEXIS Inc
F:135A
Watchlist
Price: 0.667 EUR 2.3% Market Closed
Market Cap: €25.2m

Relative Value

The Relative Value of one 135A stock under the Base Case scenario is hidden EUR. Compared to the current market price of 0.667 EUR, SCYNEXIS Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

135A Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

135A Competitors Multiples
SCYNEXIS Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
SCYNEXIS Inc
F:135A
36.1m EUR 13 -1.5 0.1 0.1
US
Eli Lilly and Co
NYSE:LLY
952.7B USD 14.6 46.2 31.1 33.2
US
Johnson & Johnson
NYSE:JNJ
584.1B USD 6.2 21.8 15.1 18.6
CH
Roche Holding AG
SIX:ROG
262.5B CHF 4.3 20.4 12 13.6
CH
Novartis AG
SIX:NOVN
238.2B CHF 5.5 22.1 13.7 17.5
UK
AstraZeneca PLC
LSE:AZN
223.5B GBP 5.1 29.3 16.2 22.9
US
Merck & Co Inc
NYSE:MRK
289.8B USD 4.5 15.9 9.9 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.9 8.1 9.5
US
Pfizer Inc
NYSE:PFE
152.4B USD 2.4 19.6 7.6 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2.5 17.3 7.3 9
P/E Multiple
Earnings Growth PEG
US
SCYNEXIS Inc
F:135A
Average P/E: 22.6
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
20.4
14%
1.5
CH
Novartis AG
SIX:NOVN
22.1
14%
1.6
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.9
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
SCYNEXIS Inc
F:135A
Average EV/EBITDA: 42.4
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.1
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.6
CH
Roche Holding AG
SIX:ROG
12
6%
2
CH
Novartis AG
SIX:NOVN
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.9
3%
3.3
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.1
1%
8.1
US
Pfizer Inc
NYSE:PFE
7.6
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.3
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
SCYNEXIS Inc
F:135A
Average EV/EBIT: 91.9
0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
18.6
7%
2.7
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
CH
Novartis AG
SIX:NOVN
17.5
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.1
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett